Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 11/18/20 | EFFECT | Notice of Effectiveness |
|
1 | |
| 11/16/20 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 | |
| 11/16/20 | UPLOAD | SEC-generated letter |
|
1 | |
| 11/10/20 | S-3 | Registration statement for specified transactions by certain issuers |
|
204 | |
| 11/10/20 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
   |
97 |
| 11/10/20 | 8-K | Current report filing |
|
7 | |
| 09/16/20 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 08/06/20 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
101 |
| 08/06/20 | 8-K | Current report filing |
|
7 | |
| 07/21/20 | SC 13G | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions |
|
12 |
